The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult ...

ADC Therapeutics (NYSE:ADCT) is one of the best multibagger penny stocks to buy right now. On December 4, Guggenheim analyst Michael Schmidt reaffirmed his Buy rating on ADC Therapeutics (NYSE:ADCT) ...

About JSKN027 JSKN027 is a first-in-class bispecific ADC designed to co-engage PD-L1 and VEGFR2. By leveraging glycan-specific conjugation technology, it precisely links its cleavable linker and ...

“These findings by our University of Hawai‘i Cancer Center research team show that drug resistance is not necessarily the end ...

Valink Therapeutics ("Valink"), a private biotechnology company developing next-generation therapeutics with a focus on bispecific antibody-drug conjugates (bsADCs) and complementary modalities, and ...

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it has ...

Merck's oral PCSK inhibitor for cholesterol, enlicitide, and its cancer antibody-drug conjugate sacituzumab tirumotecan ...

The 2025 San Antonio Breast Cancer Symposium brought plenty of data and bold new ideas to the thousands of clinicians, ...

A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...

For patients living with HER2-positive metastatic breast cancer, the recent FDA approval of trastuzumab deruxtecan (brand ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

After layoffs this fall, Mythic Therapeutics is winding down, putting all its assets up for sale and terminating its only ...